As shown in Figure 5, concomitant amplification of 2 of 3 genes significantly shortened survival times (ERBB4/C-MET: 378.0 months vs. 795.6 on average, P = 0.001; ERBB4/CD44: 483.6 months vs. 817.2 months on average, P = 0.0004; C-MET/CD44: 372.0 months vs. 822.0 months on average, P < 0.0001), and might be more prognostic of poor survival than amplification of individual gene in gastric cancer. This evidence concerns the gene ERBB4 and gastric cancer.